Tendon-bone junctions (TBJs) are frequently injured, especially in athletic settings. Healing of TBJ injuries is slow and is often repaired with scar tissue formation that compromises normal function. This study explored the feasibility of using kartogenin (KGN), a biocompound, to enhance the healing of injured TBJs. We first determined the effects of KGN on the proliferation and chondrogenic differentiation of rabbit bone marrow stromal cells (BMSCs) and patellar tendon stem/progenitor cells (PTSCs) in vitro. KGN enhanced cell proliferation in both cell types in a concentration-dependent manner and induced chondrogenic differentiation of stem cells, as demonstrated by high expression levels of chondrogenic markers aggrecan, collagen II and Sox-9. Besides, KGN induced the formation of cartilage-like tissues in cell cultures, as observed through the staining of abundant proteoglycans, collagen II and osteocalcin. When injected into intact rat patellar tendons in vivo, KGN induced cartilage-like tissue formation in the injected area. Similarly, when KGN was injected into experimentally injured rat Achilles TBJs, wound healing in the TBJs was enhanced, as evidenced by the formation of extensive cartilage-like tissues. These results suggest that KGN may be used as an effective cell-free clinical therapy to enhance the healing of injured TBJs.
INTRODUCTION
Tendons connect muscles to bones through tendon-bone junctions (TBJs), which are also referred to as enthesis, insertion sites, or osteotendinous junctions. 1 TBJs are unique structures made of tendon, a transitional fibrocartilage zone (uncalcified and calcified) and bone. [2] [3] The fibrocartilage structure acts as a shock absorber and reduces stress transmitted to tendons. 4 However, because tendons allow complex movements in multiple axes, the TBJs experience high levels of stress, making them prone to acute or chronic injuries, 1 particularly for those participating in recreational and highly-competitive sport activities. Once TBJs are injured, natural healing of the injured TBJ is extremely slow, primarily because healing takes place between two different types of tissues, i.e., tendon and bone. 5 Even when healed, the fibrocartilage zone is not completely regenerated, making it susceptible to reinjury. [6] [7] [8] Previous studies have shown that the transitional fibrocartilage zone does not regenerate in human supraspinatus reattachment, 9 infraspinatus reattachment 10 or a rabbit partial patellectomy repair model. 6, 8, 11 Treatments for these injuries almost always involve reattachment of the bone to the injured tendon by surgical juxtaposition of tendons and bones, such as in Achilles tendon and in anterior cruciate ligament (ACL) reconstruction, where a tendon graft is inserted in the bone tunnel to support tendon/bone interface healing. The outcome of ACL reconstruction largely depends on the healing of the tendon graft-bone tunnel. Unfortunately, all four zones in the injured TBJ are often not completely restored after healing, resulting in lower interface healing quality. Indeed, magnetic resonance imaging (MRI) and biopsy evaluations of human patients have shown the absence of fibrocartilage zone regeneration even several years after ACL reconstruction. 7 These studies emphasize that neither natural healing nor surgical interventions are sufficient to optimally restore the unique features of the fibrocartilage transition zone in injured TBJs. Previous studies have shown the ability of tissue engineering (TE) approaches to accelerate regeneration of the tendon/bone interface. These include the use of growth factors, [12] [13] [14] [15] [16] [17] mesenchymal stem cells (MSCs) [18] [19] and periosteal graft augmentation. [20] [21] [22] Besides these TE methods, the use of osteogenic matrix cell sheets (OMCS) has enhanced early tendon-to-bone tunnel healing. Indeed, macrophage depletion after ACL reconstruction has been shown to promote healing at the tendon/bone interface 23 and transplantation of OMCS with grafted tendons in rabbits induced bone formation. 24 In addition, implantation of a bovine-derived bone tissue scaffold into a sheep rotor cuff model also enhanced regeneration of the tendon/ bone interface. In particular, all four fibrocartilage zones at the interface were regenerated, resulting in a healed interface that was similar to the normal tendon/bone interface structure. 25 
MATERIALS AND METHODS
BMSC and patellar tendon stem/progenitor cells (PTSC) isolation and culture BMSCs were obtained from femur bones and PTSCs were isolated from patellar tendons of seven New Zealand white rabbits (4-6 months old females) based on protocols similar to those described previously. [28] [29] The protocols for using rabbits in this study were approved by Gene expression analysis in BMSCs and PTSCs by qRT-PCR Total RNA (1 mg), which was extracted from BMSCs and PTSCs in each group using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), was used to synthesize first-strand cDNA by reverse transcription using SuperScript II (Invitrogen, Grand Island, NY, USA). The incubation temperatures for the cDNA synthesis started with 65 uC for 5 min followed by cooling at 4 uC for 1 min, reverse transcription at 42 uC for 50 min and a final incubation at 72 uC for 15 min. Then, qRT-PCR was performed using the Qiagen QuantiTect SYBR Green PCR Kit (Qiagen) in a 25 mL PCR reaction volume with 2 mL cDNA (total 100 ng RNA) in a Chromo 4 Detector (MJ Research, St Bruno, Que., Canada). PCR cycling conditions consisted of an initial denaturation at 94 uC for 5 min, followed by 30-40 cycles of 1 min at 94 uC, 40 s at 57 uC, 50 s at 72 uC and a final 10 min extension at 70 uC. Rabbit-specific primers for aggrecan, collagen type II, and Sox-9, and the internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were adopted from a previous study. [30] [31] All primers were synthesized by Invitrogen and are listed in Table 1 . Expression of all genes was normalized to the control group without KGN treatment. Relative expression levels of individual genes were calculated using the 2 {DDC T method, where
and C T represents the threshold cycle of each cDNA sample. At least three C T values were used to determine the mean6standard deviation (s.d.) for each data set.
Cytochemical staining of BMSCs and PTSCs in vitro
To determine the effect of KGN on rabbit BMSC and PTSC differentiation, cells at passage 2 were seeded into 6-well plates at a density of 24 310 4 per well and treated with various concentrations of KGN. After two weeks of treatment, the cells were fixed with cold ethanol and stained within the culture plate wells with Safranin O or Alcian blue using standard protocols 32 to detect proteoglycans and collagens, respectively. ) of KGN. After 2 weeks of treatment, cells from each group were fixed in 4% paraformaldehyde in PBS at room temperature for 30 min. Then, chondrogenesis in the cells was determined by measuring collagen type II expression after immunostaining with mouse anti-collagen II (1:300) primary antibody (Cat. #CP18-100UG; Millipore, Billerica, MA), and osteogenesis expression was assessed using mouse antiosteocalcin (1:300) monoclonal antibody at room temperature for 2 h (Cat. #ab13418; Abcam, Cambridge, MA). After washing in PBS three times, the proteins were detected by incubation with FITC-conjugated goat anti-mouse IgG (1:500) for collagen type II and Cy3-conjugated goat antimouse IgG (1:500) for osteocalcin at room temperature for 2 h. After removing unbound antibodies by washing in PBS, the nuclei were stained with Hoechst fluorochrome 33342. Finally, positively stained cells were examined under fluorescence microscopy (Nikon eclipse microscope, TE2000-U, Nikon Instruments Inc., Melville, NY, USA).
In vivo injection experiments For in vivo injection experiments, 12 female SpragueDawley rats (2.5-3.5 months old) were used. The protocol for using rats in our in vivo experiments was approved by the University of Pittsburgh IACUC. Two models were used to determine the effect of KGN injections in vivo. In the first model, a wound with 1 mm diameter was created in the Achilles TBJs in both hind legs of all 12 rats using a biopsy punch (Miltex Inc., York, PA, USA). Then rats were divided into two groups based on the injections received: six rats were given 10 mL saline injections in each wound (woundonly group) and six rats received 10 mL of 100 mmol?L 21 KGN solution each in the wounded areas (wound1KGN group). The injections were given immediately after wounding and repeated on days 2, 4, 7 and 12. The KGN dosage used in the injection experiments was based on a previous study. 27 After injections, all rats were allowed free cage activities. In the second model, the intact patellar tendons in the hind legs of the wound only group received 10 mL saline, while each intact patellar tendon in the wound1KGN group received 10 mL of 100 mmol?L 21 KGN solution. Then they were all killed on day 15 post-treatment to harvest the Achilles TBJs (n512; two from each of the six rats) and the patellar tendons (n512; two from each of the six rats). After morphological examination of the wounded area, cartilage formation in each TBJ was determined by immunostaining of frozen tissue sections. For immunohistochemical analyses, both patellar and Achilles tissues were immersed in frozen section medium (Neg 50; Richard-Allan Scientific; Kalamazoo, MI, USA) in pre-labeled base molds and quickly frozen by placing in 2-methylbutane chilled in liquid nitrogen. The frozen tissue 
RESULTS

Effects of KGN on BMSCs and PTSCs in vitro
Proliferation of BMSCs and PTSCs treated with various concentrations of KGN in culture increased significantly, as revealed by a reduction in PDT (Figure 1 ). KGN significantly decreased PDT in both cell types in a concentration-dependent manner, with BMSCs reaching the lowest PDT at a KGN concentration of 5 mmol?L 21 (Figure 1 ).
Similarly, PTSCs proliferated more quickly when the KGN concentration was gradually raised from 1 nmol?
Expression levels of all three chondrogenic genes, aggrecan, collagen type II (collagen II), and Sox-9, were highly elevated in both BMSCs and PTSCs treated with KGN ( Figure 2 ) compared to control cells without KGN treatment. In BMSCs, significant increase was observed in the expression levels of aggrecan and Sox-9 even at the lowest KGN concentration (1 nmol?L 21 ) and these levels rose 
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higher with further increase in KGN levels (Figure 2a) . Specifically, aggrecan levels in BMSCs treated with 5 mmol?L 21 KGN reached the highest levels with an 8-fold increase over the non-treated control cells. Collagen II and Sox-9 mRNA levels stayed similar, with levels varying only slightly between them under all treatment conditions. Similar to aggrecan, both collagen II and Sox-9 gene expression levels also reached their maximum at 5 mmol?L 21 KGN, with a 5-fold increase when compared to the control cells without KGN treatment. On the other hand, the chondrogenic response of PTSCs to KGN treatment was different from BMSCs. While all three chondrogenic gene markers in PTSCs also increased in a dosedependent manner, the maximum expression level observed for collagen II was a 31-fold increase over control cell levels (Figure 2b) . Similarly, both aggrecan and Sox-9 mRNA levels also increased with increasing KGN concentrations in the medium, although their maximum 
Effects of KGN on tendinous tissues in vivo
To determine the in vivo effect of KGN, we first administered four injections of 100 mmol?L 21 KGN into intact rat patellar tendons and analyzed the injected area 15 days after the treatment. KGN injections induced drastic changes in the patellar tendons; they were covered with a thin layer of connective tissue, with newly formed vessels apparent across the tissue and, as a result, the shinning appearance in the saline injected control tendons ( Figure 5a ) were no longer visible (Figure 5b ). These morphological changes in the patellar tendons were corroborated by histochemical ). The cells without KGN treatment were used as a control. After being treated for 2 weeks in culture, the cells were immunostained with anti-collagen II and anti-osteocalcin antibodies to determine chondrogenic differentiation. Nuclei were stained with Hoechst fluorochrome 33342 (blue). Chondrogenic differentiation in both cell types increased after the addition of KGN in a dose-dependent manner. Bars5100 mm.
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staining, which showed intense staining for Safranin O in the KGN-treated patellar tissues (Figure 5d ) and a lack of Safranin O staining in the control tendon injected with saline ( Figure 5c ) indicating the presence of abundant proteoglycan after KGN injections. While both control and KGN treated tendons were stained with fast green, which indicated the presence of collagen, staining in control tendons was much more extensive compared to the KGNtreated tendons, indicating the presence of large amounts of neo-proteoglycan due to KGN injections.
Effects of KGN on injured TBJs in vivo
In addition to injecting KGN into intact patellar tendons, we also determined the potential of KGN to enhance wound healing in a TBJ injury model. For this, intact rat Achilles tendons (Figure 6a ) in the TBJs of the hind legs were punctured with a biopsy punch to create a wound or hole (Figure 6b) . Injection of 100 mmol?L 21 KGN indeed promoted healing of injured tissue after 15 days of treatment and appeared to form a more complete, mature and glistening cartilage-like tissue ( Figure 6d) ; in contrast, the injured tissues injected with saline looked yellowish and healing appeared incomplete (Figure 6c ). Histological analysis of these tissue sections stained with Safranin O showed that almost 90% of the KGN-injected tissue was stained positive (Figure 6f ), compared to a lack of Safranin O positive staining in the saline-injected group (Figure 6e ). Similar to the patellar tendon, fast green staining, indicating collagen, was intense only in the control (Figure 6e ), but not in the KGN-treated area of the TBJ (Figure 6f ).
DISCUSSION
Complete regeneration of TBJs after an injury continues to be a challenge in clinics. Indeed, healing at the tendon/ The normal TBJ is protected by a fibrocartilage transition zone which enables a gradual transition of mechanical property between tendon and bone, and as a result, decreases stress concentration, and enhances the strength of tissue bonding between tendon and bone. When the TBJ is injured, natural healing tends to be slow and does not completely restore the original strength of the TBJ. Therefore, surgical procedures have been adopted in clinical settings. However, thus far, surgical procedures alone have not been successful in regenerating the fibrocartilage zone in TBJs. Considering that KGN has a strong potential to induce chondrogenesis, as shown in this study, it may be a promising approach to apply KGN after reconstruction surgeries to promote healing, particularly healing of the fibrocartilage zone at the tendon/bone interface.
In clinics, tendon-bone healing is a particular challenge after ACL reconstruction, which is a common surgical procedure to re-create torn ACLs in injured knee joints to restore knee function. [33] [34] To promote the healing of the tendon graft within the bone tunnel during ACL reconstruction, researchers have used hamstring tendon transfers, 5, [35] [36] [37] [38] [39] tendon reattachment, [40] [41] cytokine administration, [14] [15] wrappings of periosteum 20 and hydroxyapatite 42 that anchors tendon to bone. All these approaches attempted to produce firm tendon-bone integration after ACL reconstruction surgeries. However, these approaches resulted in limited mechanical strength between the healed tendon and bone, because the fibrocartilage zone between the tendon graft and bone was often not established. Additionally, cell therapy approaches, such as implantation of MSCs, have been proposed to enhance healing of the tendon/bone interface, 18, [43] [44] but these approaches have downsides that make them less applicable in clinical settings. In this study, we have shown that KGN could augment and accelerate the tendon/bone interface healing because of its potential to induce chondrogenic differentiation of stem cells, as evidenced by the intense staining for chondrogenic markers collagen II and osteocalcin ( Figure 4) after KGN treatment. These findings indicate that KGN may be used to enhance tendon/bone interface healing through the direct, local delivery of KGN injections into the gap between the tendon graft and the bone surface during ACL reconstruction. It is known that within a week after ACL reconstruction, a layer of fibrovascular tissue forms in the interface between the tendon graft and bone tunnel. 23 Therefore, KGN may be used after ACL reconstruction to specifically target the stem cells in the fibrovascular/connective tissues that are already present in the interface between the tendon graft and bone tunnel during the initial healing time. In other words, this KGN approach taps into mesenchymal regenerative cells to give rise to cartilage cells that form connective tissues. These regenerative cells include chondrocytes, the only cells in the body that produce cartilage; as shown in this study, KGN activates these cells to produce cartilage tissues. Therefore, we suggest that KGN treatment could be a cell-free therapy, which will be optimal to promote healing between bones and soft tissues. caused the formation of extensive cartilage-like tissues (Figure 4 ), which may be detrimental and deter healing of TBJ. Therefore, optimal doses should be determined based on tissue type, surgery type performed and patient history before attempting to use KGN for therapeutic use. Similar dose-dependent effects of KGN on the chondrogenic differentiation of human MSCs were also reported previously. 27 This study also reported that the potential systemic toxic effects of this compound in vivo at the tested concentration (100 mmol?L 21 ) was negligible, as evidenced by the low serum level of KGN absorbed from the intra-articular space, 27 which is an advantage of using KGN as a cell-free therapy. It should be noted that this study was designed to test the feasibility of using KGN to induce chondrogenesis of stem cells and thereby enhance the healing of the tendon/bone interface. However, studies of longer term use (such as .26 weeks) and the effects of lesser amounts of KGN (such as one or two injections) are required to demonstrate whether the use of KGN injections can regenerate the fibrocartilage zone in injured TBJs, a key factor for the successful restoration of the TBJ structure and function. Moreover, the mode of KGN delivery to wounds in TBJs, in this case injection, may not be optimal; without a scaffold to control its movement, KGN cannot be guaranteed to be confined to the wound area and act in the intended location. This may be a problem because of KGNs' ability to form excessive cartilage-like tissues in unintended areas. For example, in our results (Figure 5b ), the patellar tendon was no longer visible due to over growth of patellar tissues and surrounding tissues.
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Therefore, KGN should be used with a bioscaffold, such as platelet-rich plasma, to form a matrix in the injected area and prevent KGN spreading into neighboring areas. 45 Platelet-rich plasm is a good choice for a bioscaffold, because the abundant growth factors it contains also stimulate the healing of injured tissues. In addition, for ACL reconstructions, KGN could be used along with engineered tendon matrix 46 to enhance tendon graft-bone tunnel healing and promote the formation of fibrocartilage regeneration in the interface. Use of engineered tendon matrix serves a dual purpose: on the one hand, engineered tendon matrix contains the mature matrix that stem cells need to proliferate and differentiation into tenocytes, which in turn would repair injured tendons in the TBJ; on the other hand, KGN itself could stimulate stem cells to undergo chondrogenic differentiation that would enhance the formation of the fibrocartilage zone, which could improve the healing speed and quality of tendon/ bone interface.
CONCLUSIONS
Regeneration of the TBJ after an injury is a significant challenge in clinics. This study showed that use of a small molecule called KGN could be a promising approach to augment and accelerate the formation of cartilage-like tissue in the tendon/bone interface in the TBJ as well as in ACL reconstruction. Compared to many tissue engineering approaches used in tendon/bone interface healing, KGN may be easier to apply in clinical settings as a convenient, cell-free therapy. Future research is required to determine optimal KGN dosage regimens and to evaluate the effects of KGN-scaffold composites on tendon/bone interface healing.
